Quick wins for a faster PC:
Clear out junk files and repair common Windows errorsFree Scan →Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →Repair Windows errors before they cause bigger problemsFix Now →Elevance Health’s second-quarter 2026 results show why investors should look beyond earnings per share: revenue was nearly flat year over year, the benefit expense ratio rose, and membership declined sequentially. Adjusted EPS also included a sizable below-the-line benefit. Before deciding whether the shares are attractive, assess the medical-cost trend, premium pricing, membership mix, government-program exposure and the assumptions behind management’s forward guidance—not just the headline earnings figure.
The latest official results established here are for the quarter ended June 30, 2026, released July 15, 2026. They are a dated starting point, not a substitute for checking whether Elevance has since issued newer results or material disclosures.
![[Brandon Turner]-The Book on Rental Property Investing- How to Create Wealth and Passive Income Through Intelligent Buy & Hold Real Estate Investing! (SoftCover)](https://m.media-amazon.com/images/I/51mMR6cQZCL._SL160_.jpg)
![The Intelligent Investor: The Definitive Book on Value Investing. A Book of Practical Counsel (Revised Edition)[Benjamin Graham] - [Paperback]](https://m.media-amazon.com/images/I/41c2UrXbw5L._SL160_.jpg)
What Elevance reported for Q2 2026
Elevance Health, Inc. (NYSE: ELV) reported these results in its July 15, 2026 earnings release. The figures below are company-reported; guidance is an estimate, not a realized result.
| Measure | Q2 2026 result | How to read it |
|---|---|---|
| Operating revenue | $49.8 billion, up 0.8% from Q2 2025 | Revenue growth was modest relative to the period’s earnings and operating questions. |
| Diluted EPS | $6.71 GAAP; $7.45 adjusted | The release said results included an approximately $0.80-per-share net below-the-line benefit. Do not treat adjusted EPS as a clean measure of recurring operating performance without examining that item and the company’s reconciliation. |
| Benefit expense ratio | 89.7%, up 80 basis points year over year | Elevance attributed the increase to expected elevated medical-cost trends in government businesses, partly offset by improved Individual ACA performance. |
| Medical membership | Approximately 44.9 million at June 30, 2026, down 469,000 sequentially | The company cited a commercial fee-based customer transition and anticipated Individual ACA and Medicaid attrition. |
| 2026 company guidance | At least $20.10 diluted EPS; at least $27.00 adjusted diluted EPS; at least $6.0 billion operating cash flow | These are forward-looking estimates raised by management, not reported results. |
The benefit expense ratio and membership figures give useful context to the EPS headline. Neither one, by itself, establishes whether earnings are entering a durable recovery: the ratio can move with claims, rates and business mix, while total membership does not show how much exposure comes from risk-based premiums versus fee-based arrangements.
Recommended Free Tools
#1 Best Overall
How Elevance’s businesses contribute
Elevance reports two segments. Health Benefits includes Individual, Employer Group risk-based and fee-based, BlueCard, Medicare, Medicaid and Federal Employee Program businesses. Carelon comprises CarelonRx and Carelon Services.
In Q2 2026, Health Benefits reported $42.7 billion in revenue, up 3% year over year, and $0.9 billion in operating gain; operating gain declined. Carelon reported $19.2 billion in revenue, up 6%, and $0.9 billion in operating gain. Management cited Carelon Services risk-based solutions and CarelonRx product revenue in discussing Carelon growth. These segment revenue figures should not be added to infer consolidated revenue: segment definitions and eliminations affect the consolidated total.
What to learn from medical costs and enrollment
Track the benefit expense ratio with its drivers
The benefit expense ratio compares benefit expenses with applicable premium revenue; investors often use “medical loss ratio” for the same general concept. A higher ratio means a greater share of premium revenue is being used for benefits, but a single quarter does not establish a lasting margin direction.
Elevance identifies utilization and provider unit costs as important drivers. Its filing also points to service mix, member demographics and acuity, provider-contract inflation, labor costs, new high-cost drugs and regulation. The investor question is whether these costs are temporary, whether the mix of members is changing, and whether premiums can catch up.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
Test pricing against the cost trend
Health-plan premiums are set in advance using expected cost trends. If actual claims costs rise faster than rates, or competition or regulation prevents adequate rate increases, margins may weaken. Government-program revenue also depends partly on public funding, and rate-setting schedules can leave a lag between changes in medical costs and changes in reimbursement.
Read membership by product, not just in aggregate
Redeterminations and other attrition can reduce enrollment while changing the risk profile of members who remain. A fee-based member can also affect reported membership differently from a risk-based member, whose claims exposure is more directly reflected in premium economics. Evaluate enrollment and results by Individual ACA, Medicaid, Medicare Advantage, employer risk-based and fee-based products, and federal programs where disclosures allow. A single consolidated count cannot establish whether the remaining mix is more or less profitable.
Risks that could change the earnings outlook
Medical-cost trend and rate adequacy
Claims utilization, provider prices, acuity, contract inflation, labor expenses and expensive pharmaceuticals can rise faster than premiums. Because pricing is set ahead of much of the claims experience, a favorable earnings outlook depends partly on rates matching eventual costs.
Medicaid and ACA enrollment and mix
Elevance’s filing describes elevated Medicaid trends and membership shifts around eligibility redeterminations. Enrollment losses can affect revenue, but changes in the health profile of members who leave or remain can also alter claims experience. Watch reported product-level trends rather than assuming that fewer members necessarily mean proportionately lower costs or improved margins.
Medicare Advantage payments and quality ratings
Medicare Advantage results are exposed to government rules, risk adjustment, quality ratings and payment methodology. Elevance reported that approximately 59% of its Medicare Advantage members were in plans rated at least 4.0 Stars or equivalent under the 2026 Star Ratings used to determine 2027 bonus payments. That is Elevance’s reported figure for its membership, not a market-wide statistic or a guarantee of future payment levels.
Separate the CMS notice from the DOJ litigation
In its filing, Elevance said CMS closed the enforcement process on July 13, 2026, concerning certain diagnosis-code submissions for dates of service from 2015 through April 2023; sanctions would not be imposed after required steps were completed. The company reported a $342 million payment and a $593 million accrual at June 30, 2026, and said the ultimate estimate could differ.
That closure did not resolve a separate Department of Justice lawsuit concerning Medicare risk-adjustment allegations. Elevance said the litigation remained ongoing and its outcome could not then be determined. Treat the two matters as distinct when assessing legal exposure.
Regulatory, legal and operational execution
The 10-Q identifies risks involving changes in health and insurance laws, Medicare and Medicaid compliance, litigation and government investigations, cyber and privacy incidents, information systems and technology, provider contracting, competition, debt and capital requirements. Elevance reported no material changes to the risk factors in its 2025 Form 10-K as of June 30, 2026. That statement does not remove the underlying risks; it describes the company’s filing position at that date.
Best Value
- Basic Books Power and Progress Our Thousand-Year Struggle Over Technology and Prosperity.
- ABISBOOK.
- Basic Books.
Separate management confidence from evidence
CEO Gail K. Boudreaux said the company was increasing targeted investment in medical-cost management, member experience, provider connectivity, operating efficiency and Carelon value-based solutions. She also expressed confidence in returning to at least 12% adjusted EPS growth in 2027, measured from the 2026 earnings baseline. That is management’s stated outlook, not an independently established forecast. Investors can test it against subsequent benefit expense ratios, rate adequacy, product-level membership, Carelon operating gains and cash generation.
How to evaluate ELV’s valuation without inventing a target
A valuation requires a date-stamped share price and a consistent earnings denominator. No price target or peer multiple is established by the company results summarized above, so a specific fair value or current P/E cannot be inferred from them alone.
- Fix the measurement date. Record ELV’s market price and the date it applies to. Use the same date for any comparison and identify whether the price is intraday or a closing price.
- Choose and label the earnings basis. Calculate price divided by diluted EPS only after specifying GAAP or adjusted earnings and whether the denominator is trailing, current-year guidance or a forward estimate. Do not mix an adjusted numerator or denominator with a GAAP figure without clearly explaining the difference.
- Treat guidance as a scenario. A multiple using management’s adjusted EPS guidance is guidance-based, not a valuation on realized earnings. Account for the release’s approximately $0.80-per-share net below-the-line benefit when considering how representative the adjusted earnings base may be.
- Stress the operating assumptions. Model plausible changes in the benefit expense ratio, premium rate adequacy, membership and product mix, Medicare Advantage performance, Medicaid margin recovery, and Carelon growth and operating gain. A modest change in medical costs can matter more than a small change in enrollment if rates do not keep pace.
- Check cash, debt and capital needs. Compare earnings with operating cash flow, debt and capital requirements, then consider capital returns. Cash generation can help assess earnings quality, but it does not eliminate the need to evaluate regulatory capital and other obligations.
- Use consistent peer definitions if comparing insurers. Align GAAP versus adjusted EPS, expense-ratio trends, risk-based membership mix, government-program exposure, cash conversion, debt, capital returns and valuation period. A peer comparison using mismatched definitions can make relative value misleading.
Primary documents to check before investing
Use Elevance Health’s July 15, 2026 Q2 earnings release for the reported quarter, reconciliation and guidance, and its 10-Q for segment, membership, risk and legal disclosures. Before relying on those documents for a current decision, check the company’s investor-relations materials and SEC filings for any subsequent results, amended disclosures or material events. The figures and legal status described above are tied to the dates stated, not to future periods.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
